- Home
- RGLS vs OTLK Comparison
RGLS vs OTLK Comparison
Compare RGLS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLS
- OTLK
- Stock Information
- Founded
- RGLS 2007
- OTLK 2010
- Country
- RGLS United States
- OTLK United States
- Employees
- RGLS N/A
- OTLK N/A
- Industry
- RGLS Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGLS Health Care
- OTLK Health Care
- Exchange
- RGLS Nasdaq
- OTLK Nasdaq
- Market Cap
- RGLS 106.7M
- OTLK 121.8M
- IPO Year
- RGLS 2012
- OTLK 2016
- Fundamental
- Price
- RGLS $1.48
- OTLK $5.64
- Analyst Decision
- RGLS Strong Buy
- OTLK Strong Buy
- Analyst Count
- RGLS 6
- OTLK 7
- Target Price
- RGLS $10.33
- OTLK $48.20
- AVG Volume (30 Days)
- RGLS 263.0K
- OTLK 250.3K
- Earning Date
- RGLS 11-07-2024
- OTLK 08-14-2024
- Dividend Yield
- RGLS N/A
- OTLK N/A
- EPS Growth
- RGLS N/A
- OTLK N/A
- EPS
- RGLS N/A
- OTLK N/A
- Revenue
- RGLS N/A
- OTLK N/A
- Revenue This Year
- RGLS N/A
- OTLK N/A
- Revenue Next Year
- RGLS N/A
- OTLK N/A
- P/E Ratio
- RGLS N/A
- OTLK N/A
- Revenue Growth
- RGLS N/A
- OTLK N/A
- 52 Week Low
- RGLS $1.08
- OTLK $4.61
- 52 Week High
- RGLS $3.79
- OTLK $13.32
- Technical
- Relative Strength Index (RSI)
- RGLS 44.54
- OTLK 51.47
- Support Level
- RGLS $1.47
- OTLK $4.96
- Resistance Level
- RGLS $1.65
- OTLK $5.45
- Average True Range (ATR)
- RGLS 0.11
- OTLK 0.29
- MACD
- RGLS -0.00
- OTLK 0.13
- Stochastic Oscillator
- RGLS 15.79
- OTLK 92.62
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.